Site icon pharmaceutical daily

Allotex begins with final phase of Presbyopia clinical trials

BusinessWire

BOSTON–(BUSINESS WIRE)–Allotex, a Boston based private company developing the TransForm Corneal
Allograft (TCA) for the treatment of presbyopia (reading glasses) and
hyperopia (far sightedness), is pleased to report that over 50 eyes have
been treated in the first phase of its clinical trials.

The TCA is created using natural human corneal tissue that has been
shaped using high precision patented and proprietary technology. These
shaped lenticules are placed in the patient’s natural cornea with the
aim of reducing or eliminating the need for spectacles.

Dr. Arthur Cummings of the Wellington Eye Center in Dublin commented on
his experience with the TCA for presbyopia: “My impression of TCA inlays
is very positive on a number of fronts. The patient acceptance has been
better than with any other inlay that I have used before, the patient
satisfaction is very high, and every time I look at the pristine cornea
and find it difficult to even see the inlay, I am reassured about the
bio-compatibility.”

From Medipol University, Professor Aiylin Kilic notes that she has seen
positive results using the allogenic TCA in treating patients with
presbyopia, hyperopia, and hyperopic presbyopia, and patients with
regression after hyperopic LASIK treatment. “I feel very comfortable
when I recommend the TCA for refractive treatment because the most
important advantages of allogenic corneal inlays are safety and
reversibility. The use of allogenic tissue provides biocompatibility and
very good integration into the cornea, which is not possible with a
synthetic inlay.”

Allotex CEO, Dr. David Muller states: “We are very pleased with the
progress and the results of our initial clinical trial. Patient
satisfaction has been high, surgeons are comfortable with the procedure,
and we are excited about moving into the final phase of the European
clinical trials. We expect to be able to fully commercialize our
TransForm products in Europe within the next 12 months.”

Joining Drs. Cummings and Kilic in the final phase of the clinical
trials are:

Exit mobile version